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Several studies have shown that type 1 interferons (IFNs) exert multiple biological effects on both innate
and adaptive immune responses. Here, we investigated the pathogenicity and immunogenicity of
recombinant rabies virus (RABV) expressing canine interferon α1 (rHEP-CaIFNα1). It was shown that
Kun Ming (KM) mice that received a single intramuscular immunization with rHEP-CaIFNα1 had an
earlier increase and a higher level of virus-neutralizing antibody titers compared with immunization of
the parent HEP-Flury. A challenge experiment further conﬁrmed that more mice that were immunized
with rHEP-CaIFNα1 survived compared with mice immunized with the parent virus. Quantitative real-
time PCR indicated that rHEP-CaIFNα1 induced a stronger innate immune response, especially the type
1 IFN response. Flow cytometry was conducted to show that rHEP-CaIFNα1 recruited more activated B
cells in lymph nodes and CD8 T cells in the peripheral blood, which is beneﬁcial to achieve virus
clearance in the early infective stage.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Rabies is an ancient zoonosis that still accounts for 55,000
human deaths annually, most of which occur in developing
regions of the world (World Health Organization, 2010). Rabies
virus enters neurons at peripheral sites and travels through the
spinal cord to the brain of the infected host, often inducing
aggression that facilitates the transfer of virus to a new host
(Schnell et al., 2009). Rabies has a high associated mortality rate,
and thus, an effective vaccine plays a vital role in controlling rabies
outbreaks. Animal vaccination barriers should be set up to prevent
human rabies because human infections occur through contact
with rabid domestic dogs or other canidae (Hicks et al., 2012).
Rabies virus (RABV) itself is a favorable vaccine vector. Much
research has been focused on the application of recombinant RABV
(rRABV) expressing foreign proteins (Gomme et al., 2011; Verardi
et al., 2012; Yilma et al., 2010). Expression of multiple copies of
RABV G (Schutsky et al., 2013; Liu et al., 2014; Zhang et al., 2012)
and expression of some immune-related genes (Wang et al., 2011;
Wen et al., 2011; Zhao et al., 2010) have also been conﬁrmed to
lead to enhanced immunogenicity and viral attenuation. As a vital
innate-response gene, interferon (IFN), especially type 1 interferon
(IFN1), not only enhances antigen presentation and the production
of immune response mediators, such as cytokines and chemo-
kines, but also affects adaptive immunity. For example, type 1 IFNs
can augment antibody production by B cells and amplify the
effector function of T cells (Ahlenstiel et al., 2011; Ivashkiv and
Donlin, 2014; Kohlmeier et al., 2010; Staudt et al., 2010).
According to our previous study, appropriate doses of canine
interferon α1 enhanced the immunogenicity of rabies vaccine
when they were administered simultaneously in dogs (data not
shown). Type 1 interferon possessed the characteristic of species
speciﬁcity, and canine interferon α subtypes showed much lower
antiviral activity on the bovine, swine, rabbit, and feline cells than
canine cell (Taira et al., 2005). The activity of CaIFNα1 in mouse
was investigated via detecting the activation of STAT1 in murine
cells by immunoﬂuorescence microscopy. We found that the
higher level of pSTAT1(Y701) was detected in BSR, NA, and
Balb/c-3T3 cells after treatment with CaIFNα1, which indicates
that mouse is sensitive to CaIFNα1 and makes it permissible to use
mouse model in our earlier animal experiment. In this study, the
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recombinant high egg passage Flury strain (HEP-Flury) of RABV
that contains the canine interferon α1 gene (rHEP-CaIFNα1) was
investigated in mouse. Our study indicated that recombinant
RABV not only decreases the pathogenicity but also increases the
immunogenicity of RABV.
Results
Recombinant RABV construction
Insertion of the canine IFNα1 gene was conﬁrmed by sequen-
cing the fragment with the infectious clones. Recombinant RABVs
were rescued using the procedures described by Inoue et al.
(2003) and designated rHEP-CaIFNα1 (Fig. 1A)
rRABV in vitro characterization
To characterize the rRABV in vitro, viral growth kinetics were
examined in BSR cells and NA cells. As shown in Fig. 1B, difference
between the values was observed between recombinant virus and
the parental virus, indicating that there is effect on viral growth
caused by the insertion of the CaIFNα1 gene. The restriction effect
of canine interferon on viral replication seemed much stronger in
NA cells than BSR cells, which indicated that NA cells were more
sensitive to interferon. The ability of the rHEP-CaIFNα1 to produce
CaIFNα1 was determined by measuring CaIFNα1 in virus-infected
BSR cells using an ELISA kit. As shown in Fig. 1C, CaIFNα1 was
produced by rHEP-CaIFNα1 in a dose-dependent manner. No
CaIFNα1 product was detected in the supernatant of BSR cells
infected with the parent virus HEP-Flury.
Immunoﬂuorescence microscopy
Interferon initials the host antiviral response via JAK/STAT
signaling pathway. The phosphorylation of STAT1 indicated activ-
ity of interferon in host cells. As shown in Fig. 2, pSTAT1(Y701) was
highly expressed in three kinds of mouse cells incubated with
CaIFNα1 than mock control, which was suggested that mouse is
sensitive to CaIFNα1.
Apoptosis detection
It has been shown that expression of IFN induces apoptosis
(Kalliolias and Ivashkiv, 2010; Kotredes and Gamero, 2013).
An Annexin V-FITC Apoptosis Detection Kit (Keygentec, China)
was used to detect apoptosis in our study. As shown in Fig. 3, the
early apoptotic cells (Annexin V-FITC-positive and PI-negative)
were located in the lower right quadrant. The late apoptotic or
necrotic cells (Annexin V-FITC-positive and PI-positive) were
located in the upper right quadrant. The healthy cells (negative
for both probes) were located in the lower left quadrant.
The results are represented as the percentage of Annexin V-FITC-
positively- and PI-negatively-stained cells (located in lower right
quadrant) among total cells. As our data showed, the induction of
apoptosis in cultured cells (both NA cells and BSR cells) infected
with rHEP-CaIFNα1 was signiﬁcantly higher than cultured cells
infected with parent virus.
rRABV's pathogenicity in mice
According to the method described above, infected mice were
monitored daily for 4 weeks for weight changes, for development
of disease, and for death. When infected with HEP-Flury at the
doses of 105 FFU, infected mice lost more body weight than when
they were infected with rHEP-CaIFNα1 (Fig. 4). Most of the mice
regained their prechallenge body weight by 16 days post-infection
(dpi) when they were infected with rHEP-CaIFNα1, while the mice
infected with HEP-Flury did not regain their prechallenge body
weight until 25 dpi (Fig. 4). No overt clinical symptoms, such as
abnormal behaviors, or any neurological signs, were observed
among these mice. These data indicated that recombinant RABVs
carrying CaIFNα1 did not increase RABV virulence, but that they
reduced viral pathogenicity.
Fig. 1. Construction of recombinant RABV and characterization of rRABV in vitro. (A) Recombinant RABV is constructed as described in Materials and methods. N,
nucleoprotein; P, phosphoprotein; M, matrix protein; G, glycoprotein; L, RNA-dependent RNA polymerase. (B) Virus growth curves in BSR and NA cells. Virus growth curves
are determined by infecting BSR cells (solid line) or NA cells (dashed line) with either the HEP-Flury or rHEP-CaIFNα1 virus at a multiplicity of infection (MOI) of 0.01. At days
1, 2, 3, 4, and 5 after infection, the culture supernatants are harvested, and viral titers are determined. (C) CaIFNα1 expression in cells culture supernatants. CaIFNα1
expression is determined using infected BSR cells with either the rHEP-CaIFNα1, or HEP-Flury at an MOI of 0.01, 0.1, or 1. After incubation at 34 1C for 24 h, the culture
supernatants are harvested, and the amounts of CaIFNα1 are determined using a canine IFNα enzyme-linked immunosorbent assay (ELISA) kit, according to the
manufacturer's instructions. The positive control (CaIFNα) is supplied with the kit.
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rRABV's immunogenicity
Each group of mice (n¼10) was immunized once via the
intramuscular route with different doses of rHEP-CaIFNα1 or
HEP-Flury (5102, 5103, or 5104 FFU per mouse). Blood
samples were collected at 7 dpi, 14 dpi, and 21 dpi, and serum
was used for determination of VNA using ELISA. Overall, the level
of VNA is dose dependent for all viruses. Fig. 5A, B, and C show the
VNA levels in immunized mice at 7 dpi, 14 dpi, and 21 dpi,
respectively. A level of 0.5 international units (I.U.) is considered
Fig. 2. Immunoﬂuorescence microscopy. BSR cells, NA cells, Balb/c-3T3 cells are cultured in a glass bottom cell culture dish and incubated with 100 U/ml CaIFNα1 at 37 1C for
1 h. Mock treatment is conducted by inoculation with DMEM. After incubation, the cells are ﬁxed and permeabilized in 0.5% TritonX-100 in phosphate-buffered saline (PBS).
The cells are then stained with pSTAT1(Y701)-PE and DAPI. Confocal laser scanning microscopy is performed with a Zeiss LSM780 laser system using a Zeiss LSCM 7DUO
microscope. Excitation of Alexa Flour 488 nm, PE and DAPI occurred at wavelengths of 575 nm, and 460 nm, respectively.
Fig. 3. Apoptosis detection. Annexin V-FITC and PI staining for ﬂow cytometry detection of apoptosis of NA and BSR cells induced by HEP-Flury and rHEP-CaIFNα1. The cells
are incubated with virus for 24 h prior to being stained with Annexin V-FITC and PI. The early apoptotic cells (Annexin V-FITCþ and PI) are located in the lower right
quadrant. The results are represented as the percentage of Annexin V-FITCþ and PI cells among total cells.
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protective from RABV infection. The level of VNA was under 0.5 IU
in mice immunized with all the viruses at 7 dpi although
signiﬁcantly higher level of VNA was detected in mice immunized
with rHEP-CaIFNα1 than with HEP-Flury. Signiﬁcantly higher VNA
titers were also detected in mice immunized with rHEP-CaIFNα1
than in those induced by immunization with the parent virus, and
HEP-Flury, at both 14 dpi and 21 dpi, respectively. To investigate if
the higher VNA titers correlate with better protection, immunized
mice were then challenged with 50 LD50 of virulent CVS-24 via
intracranial route on day 23 after vaccination and observed for
development of disease and death for 2 weeks. As shown in Fig. 6,
signiﬁcantly more survivors were observed among those immu-
nized with rHEP-CaIFNα1 than among those immunized with the
parent HEP-Flury virus, when the smaller doses (5102 and
5103 FFU per mouse) were used. More survivors were also
observed among mice immunized with rHEP-CaIFNα1 than among
mice immunized with the HEP-Flury, but no signiﬁcant difference
was detected with the dose of 5104 FFU per mouse. Taken
together, these data indicate that rRABV expressing CaIFNα1
provides better protective immunity than the parent virus.
Induction of innate immune responses and viral growth in vivo
To investigate the ability of the rHEP-CaIFNα1 to induce innate
immune responses, especially the type 1 IFN response, BALB/c
mice were infected with 105 FFU of each virus by intramuscular
route, and at 3 dpi or 6 dpi, mice were humanely sacriﬁced and
muscle harvested for measuring the expression of interferon-
induced genes (IIGP1, IRF3, ISG20, MusIFNα1, PDCD4, and STAT1)
using quantitative real-time PCR as described above. Details are
shown in Fig. 7. We found that rHEP-CaIFNα1 induced much
stronger interferon-related innate immune response in immu-
nized mice than HEP-Flury. On the other hand, there was no
difference in the fold changes of PDCD4 (Programmed Cell Death
4) compared with that of control RABV, which indicated that rHEP-
CaIFNα1 did not cause more apoptosis than the parent HEP-Flury
virus. No activation of apoptosis during in vivo study might be due
to the low level of virus replication and IFN production at the site
of inoculation, as shown in Fig. 7. Data showed that the rHEP-
CaIFNα1 N mRNA expression level was much lower than parent
HEP-Flury virus, which indicated that the interferon responses
induced by rHEP-CaIFNα1 obstructed the viral replication in vivo.
Effects of rRABV on the recruitment of B and T cells
To determine if the expression of interferon-induced genes
results in inﬂuence on the recruitment of B and T cells, ﬂow
cytometry was performed to quantify the immune cells in the
peripheral blood and lymph nodes. The populations of activated B
cells in the inguinal lymph node were differentiated using the cell
surface markers CD19 and CD40. The populations of CD4 T cells
and CD3 T cell in the peripheral blood were differentiated using
CD4 and CD8, respectively, while CD3 was used as a maker for all T
cells. Fig. 8A shows representative ﬂow cytometric plots of CD4
T cells (CD3-positive and CD4-positive) and CD8 T cells
(CD3-positive and CD8-positive), and Fig. 8C shows plots of B cells
(CD19-positive and/or CD40-positive) at days 3, 5, or 7 after
infection with each RABV. As shown in Fig. 8B and D, more
immune cells (CD8 T cells as detected by CD8 and CD3 and
activated B cells as detected by CD19 and CD40) were detected
in mice infected with rHEP-CaIFNα1 than in mice infected with
the parent virus.
Discussion
Recent studies showed that the activation of innate immune
responses is one of the mechanisms by which RABV is attenuated
(Leroy et al., 2006). Chemokine overexpression can be a beneﬁt if
the expression is transient, but it can be harmful to the host if the
expression is persistent during RABV infections (Kuang et al.,
2009; Niu et al., 2011). Interferon, synthesized and secreted from
infected cells, in turn directed ampliﬁcation of the response and
transcription of a broader range of antiviral genes in both auto-
crine and paracrine manners, leading to establishment of an
antiviral state. Type 1 IFN responses are ﬁne-tuned by host factors
(Ivashkiv and Donlin, 2014), which make them promising biologi-
cals to enhance the immune effect. Similar to other viruses,
RABV has evolved effective mechanisms to obstruct the anti-viral
Fig. 4. Body weight change of mice infected with recombinant RABV. The
pathogenicity of recombinant rHEP-CaIFNα1 is determined by infecting BALB/c
mice (6–7 weeks of age) intracranially with 105 FFU of either the HEP-Flury, rHEP-
CaIFNα1 virus or with medium alone (mock infection). Body weight is monitored
daily. Data are obtained from 5 mice in each group and presented as the mean
value7standard error (SE).
Fig. 5. VNA titers in mice immunized with recombinant RABV. Groups of 10 KM mice (6–7 weeks of age) are immunized via the intramuscular route with serial 10-fold
dilutions of HEP-Flury, or rHEP-CaIFNα1. At days 7 (A), 14 (B), and 21 (C) after immunization, the peripheral blood is obtained, and the serum is used to determine VNA titers,
using the ELISA assay, according to the manufacturer's instructions. A level of 0.5 international units (I.U.) is considered protective from RABV infection. Data are analyzed
using GraphPad Prism 5. Asterisks indicate signiﬁcant differences among the experimental groups, as calculated by one-way ANOVA (*po0.05; **po0.01; ***po0.001).
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responses in the host (Randall and Goodbourn, 2008). In previous
studies, RABV phosphoprotein P was conﬁrmed to be an
IFN antagonist that plays a major and multifunctional role in
disturbing interferon gene expression, interferon-induced STAT
signaling, and the functions of antiviral protein (Lieu et al., 2013;
Vidy et al., 2007; Wiltzer et al., 2014). Although RABVs have
developed advanced countermeasures against the IFN system,
the interferon-mediated mechanisms are still the main factors
restricting RABV replication in vivo (Carty et al., 2014; Faul et al.,
2009; Lafon, 2011; Schoggins et al., 2011). Lafon et al. showed that
although the neuroinvasive RABV strain CVS-NIV reduces type
1 IFN signaling, an early and transient type 1 IFN response is still
triggered in the infected neuronal cells and nervous system (NS)
(Carty et al., 2014), and this type 1 IFN response is efﬁcient enough
to reduce neuroinvasiveness and pathogenicity and partially
protect the host from fatal infection (Chopy et al., 2011). Faul
et al. constructed a recombinant rabies virus expressing both IFN-
β and HIV-1 Gag. The rRABV expressing IFN-β (IFNþ) is highly
attenuated and the mice immunized with IFNþ RABV had a
signiﬁcantly greater number of activated CD8 T cells, which
indicated that interferon expressed by rabies virus-based HIV-1
vaccine vector could serve as a molecular adjuvant (Faul et al.,
2008).
In the present study, the recombinant RABV rHEP-CaIFNα1 was
investigated and compared with the parent HEP-Flury virus. The
viral titers of recombinant RABV were slightly lower than those of
the parent virus in BSR cells and much lower than those of the
parent virus in NA cells (Fig. 1B). The BSR cells cannot produce IFN
(Marschalek et al., 2009; Rieder and Conzelmann, 2011) but have
an IFN-α/β receptor. Infection of RABV stimulated the responses of
IFN, and viral replication of rHEP-CaIFNα1 could be inhibited for
this reason in BSR cells (Niu et al., 2013). In NA cells, which are
IFN-competent, the restriction effect of IFN on viral replication was
much stronger.
Our study indicated that pSTAT1(Y701) was higher expressed in
mouse cells incubated with CaIFNα1 than mock control (Fig. 2).
After being conﬁrmed its sensibility to CaIFNα1, mouse was used
to investigate the pathogenicity and immunogenicity of rHEP-
CaIFNα1. Mice infected with rHEP-CaIFNα1 regained their body
weight sooner than the other mice that were infected with HEP-
Flury (Fig. 4). Although body weight loss occurred, mice infected
with both the parent virus and rHEP-CaIFNα1 did not show overt
clinic symptoms, abnormal behavior, or any neurological signs.
Besides, it was shown that mice infected with rHEP-CaIFNα1
suffered less body weight loss than mice infected with the parent
virus. The result indicated that CaIFNα1 expression reduced the
rRABV pathogenicity.
A higher VNA level (Fig. 5) and better protection (Fig. 6) were
detected among mice immunized with the recombinant virus than
among mice immunized with the parent virus. In addition, the
mice immunized with recombinant RABV responded to viral
infection sooner than mice immunized with a parent virus.
Another characteristic of the rRABV is that a relatively small dose
of rHEP-CaIFNα1 is needed to induce sufﬁcient VNA and show
effective protection. As our data showed, when the smaller
immunized doses (5102 and 5103 FFU per mouse) were used,
signiﬁcantly more survivors were observed among those immu-
nized with rHEP-CaIFNα1 than among those immunized with the
parent HEP-Flury virus (Fig. 6).
In order to investigate the mechanism of how rHEP-CaIFNα1
enhances immunogenicity and viral attenuation, interferon-induced
gene expression at the inoculation site is evaluated using quantita-
tive real-time PCR. Our data showed that the recombinant RABV
rHEP-CaIFNα1 induced a stronger innate immune response in mice
with the higher expression level of ISG20, IIGP1, IRF3, and STAT1
(Fig. 8A). ISG-encoded proteins restrain pathogens via several
mechanisms including inhibiting viral transcription, translation
and replication; degrading viral nucleic acids; and altering cellular
lipid metabolism (Degols et al., 2007). IIGP1 belongs to a well-
deﬁned family of 47-kDa GTPase whose members are present at
low resting levels in mouse cells, but are strongly induced tran-
scriptionally by interferons, and are implicated in cell-autonomous
resistance to intracellular pathogens (Uthaiah et al., 2003). IRF3 was
Fig. 6. Survivorship curves of mice challenged with CVS24. Mice immunized with
either HEP-Flury, rHEP-CaIFN, or DMEM (control) are challenged via the intracra-
nial route with 50 LD50 of CVS24 on day 23 after immunization and observed daily
for 2 weeks. The number of survivors is recorded and compared. Data are analyzed
using GraphPad Prism 5 with Gehan–Breslow–Wilcoxon Test or Log-rank (Mantel–
Cox) Test. The difference in survival between mice immunized with rHEP-CaIFNα1
and mice immunized with HEP-Flury is signiﬁcant when the smaller doses (5102
and 5103 FFU per mouse) are used (po0.05).
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found to be essential for MAVS/IPS-1-directed ISG transcription and
IFN-β secretion during virus infection (Sen et al., 2011; Zhang et al.,
2013). As an important component of the type 1 IFN signaling
pathway, STAT1 is widely expressed and thus most cell types are
competent to mount type 1 IFN-dependent responses with other
necessary components, such as IFNAR, JAK1, TYK2, STAT2, and IRF9.
On the other hand, the magnitude of this signaling is balanced by
opposing mechanisms that limit expression of IFNAR-JAK-STAT
signaling components (Ivashkiv and Donlin, 2014). Though the
induction of apoptosis in cultured BSR and NA cells infected with
rHEP-CaIFNα1 was signiﬁcantly higher than that infected with
parent virus, the PDCD4 (Programmed Cell Death 4) level induced
by rHEP-CaIFNα1 was similar to that of HEP-Flury, which may due
to the low level of virus replication and IFN production at the site of
inoculation. This indicated that rHEP-CaIFNα1 did not tend to
deepen the degree of apoptosis in vivo, which may cause organism
damage, compared with the parent HEP-Flury virus (Baloul and
Lafon, 2003; Subedi et al., 2013). The interferon responses induced
by rHEP-CaIFNα1 also impacted the viral replication in vivo (Chopy
et al., 2011). The relative quantity of RABV N mRNA (relative to
reference gene GAPDH) among mice infected with rRABV expres-
sing CaIFNα1 was analyzed. As shown in Fig. 7, rHEP-CaIFNα1 N
mRNA expression was lower than parent HEP-Flury virus, suggest-
ing that interferon-induced responses interfered the viral growth
in mice.
Our study indicated that the recombinant RABV expressing
IFNα1 (rHEP-CaIFNα1) recruited and/or activated more B cells or
CD8 T cells in lymph nodes or the peripheral blood than did the
parent virus, which may be related to interferon-induced innate
responses and the reduction of viral load at an early rRABV
infection stage (Fig. 8). Because CD19 and CD40 are B cell-
speciﬁc surface markers that are present in the pre-B cells, the
immature B cell and mature B cell surfaces are associated with B
cell activation (Castigli et al., 1996), and CD19-PerCP and CD40-
FITC were used to detect activated B cells in our study. Our data
suggest that activated B cells are recruited in lymph nodes of mice
Fig. 7. Expression of interferon-related immune genes. BALB/c mice are infected with 105 FFU of each virus via the intramuscular route, and at 3 dpi or 6 dpi, mice are
sacriﬁced humanely and muscles are harvested for measuring the expression of interferon-related genes (STAT1, IRF3, IIGP1, PDCD4, ISG20, and MusIFNα1) by quantitative
real-time PCR in a CFX384 Real-Time System. The expression levels of target genes, IIGP1, IRF3, PDCD4, STAT1, and mouse interferon alpha (MusIFNα1), are normalized to
those of reference gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The RABV N mRNA and CaIFNα1 mRNA are quantitated relative to the GAPDH expression level.
Data are analyzed using BioRadCFX Manager and GraphPad Prism 5. Asterisks indicate signiﬁcant differences among the experimental groups, as calculated by one-way
ANOVA (*po0.05; **po0.01; ***po0.001).
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immunized with rHEP-CaIFNα1, and induce interferon responses
that are greater than parent virus at 3 dpi, 5 dpi and 7 dpi,
suggesting that recombinant RABV induced a stronger and quicker
response in immunized mice in the early infective stage (Braun
et al., 2002; Fink et al., 2006; Le Bon et al., 2006). The percent of
CD3þCD8þ T cells in blood among mice immunized with rHEP-
CaIFNα1 maintained higher level than mock at day 7 post-inocu-
lation, while the CD3þCD8þ T cells in blood among mice immu-
nized with parent HEP-Flury virus just started their upward
momentum. This result may be relevant to the reduction of viral
load in mice infected with rHEP-CaIFNα1 that induce interferon
responses (Fig. 7). As previous studies suggested, the elaboration
of the anti-viral CD8 T cell responses following infection is a
cornerstone of the adaptive immune responses, and they are vital
for controlling acute infections, containing persistent infections,
and conferring long-lived protection to viral re-exposures (Carty
et al., 2014; Zhang and Bevan, 2011). The increased CD8 T cell
response to the infection was considered to be beneﬁcial. In
addition, our data showed that rHEP-CaIFNα1 recruited more
CD19þCD40þ B cells in lymph nodes among immunized mice
than parent virus, which may contribute to the higher VNA
induced by rHEP-CaIFNα1 than the parental virus. The stronger
response of immune cells may be related to the enhanced
immunogenicity and reduced pathogenicity of recombinant RABV
(Cox et al., 2013; Le Bon et al., 2006).
The immunization in dogs is on the schedule, and the outlook
of application in emergency treatment after exposure is also
promising. In summary, our studies demonstrate that IFNα1
expression results not only in reduced RABV pathogenicity but
also in enhanced RABV immunogenicity by affecting the innate
and adaptive immunity in mice. Recombinant RABV that expresses
CaIFNα1 has the potential to be developed as an avirulent RABV
vaccine.
Materials and methods
Cells, virus, antibodies, and animals
BSR cells and BHK-21 cells were maintained in Dulbecco's
modiﬁed Eagle's medium (DMEM) (Gibco, Invitrogen, China)
containing 10% FBS. rRABV was rescued in BHK-21 cells and
propagated in BSR cells. Challenge virus standard 24 (CVS-24)
was propagated in sucking mice brains. Fluorescein isothiocyanate
(FITC)-conjugated antibody against the RABV N protein was
purchased from Fujirabio Inc., Malvern, PA. Antibodies used
for ﬂow cytometric analysis or immunoﬂourescen microscopy,
such as CD4-PerCP(RM4-5), CD8a-PE(53-6.7), CD3e-FITC
(145-2C11), CD19-FITC(1D3), CD40-PE(3/23), and pSTAT1(Y701)-
PE(4a), were purchased from BD Pharmingen (USA). Annexin
V-FITC Apoptosis Detection Kit (Keygentec, China) was used to
detect the early apoptotic cells after infection with rabies virus.
Female BALB/c and KM mice were purchased from Center for
Laboratory Animal Science, Southern Medical University and
housed in the animal facility of the College of Veterinary Medicine,
South China Agricultural University. All animal experiments were
carried out in compliance with national standard Laboratory
Animal Requirements of Environment and Housing Facilities
(CALAS, GB 14925-2001) and following Guidelines on the Humane
Treatment of Laboratory Animals.
Fig. 8. Recruitment and activation of CD8 T cells and B cells. BALB/c mice are infected via the intramuscular route with 1105 FFU rHEP-CaIFNα1 or HEP-Flury, and
peripheral blood or inguinal lymph nodes are harvested at 3, 5, and 7 days post-infection. Single-cell suspensions are prepared and stained with antibodies to T cell markers
(CD3-FITC, CD8-PE, and CD4-PerCP) or B cell markers (CD19-PE and CD40-FITC). Data collection and analysis are performed using a Beckmen FC 500 ﬂow cytometer and FCS
Expression software. (A) CD3-FITC is used to gate all T cells in the blood. The plots in lower-right quadrant of each scatter plot represent CD3þCD8þ cells. (B) The line chart
shows differences in the magnitude of CD8 T cell recruitment at days 3, 5, and 7 with the rRABV and parent virus. (C) The plots in upper-right quandrant of each scatter plot
represent CD19þCD40þ B cells. (D) The line chart shows the different magnitude of recruitment and/or activation of B cells at days 3, 5, and 7 with the rRABV and
parent virus.
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Construction of recombinant RABV cDNA clones
High egg passage Flury strain (HEP-Flury) of RABVs was used as
the parent RABV. Based on the HEP-Flury, a recombinant RABV
infectious clone was constructed by inserting CaIFNα1 between G
and L genes to obtain rHEP-CaIFNα1.
Rescue of recombinant RABV from cloned cDNA
Recombinant RABVs were rescued as described previously
(Inoue et al., 2003). Brieﬂy, BHK-21 cells grown in 12-well plates
were transfected with 1.25 mg of the full-length clone and
0.3125 mg, 0.15625 mg, 0.09375 mg, and 0.0625 mg of pcDNA-N, -P,
-G and -L, respectively using 7.5 ml of SuperFect transfection
reagent (Qiagen, GER) in a ﬁnal volume of 75 ml. The transfection
was allowed to proceed for 3 h and then the transfecting medium
was removed and replaced with fresh DMEM containing 10% FBS.
After incubation at 37 1C for 2 days, the culture medium was
removed and fresh medium with 5% FBS was added to the cells.
After incubation for another 4 days, the culture medium was
harvested and the cells were examined for the presence of rescued
virus under a ﬂuorescence microscope (AMG, USA) using FITC-
conjugated antibodies against the RABV N protein.
Virus propagation and titration
All RABV strains were propagated in BSR cells. For virus
titration by direct ﬂuorescent antibody assay (dFA), BSR cells in
96-well plates were infected with serial 10-fold dilutions of the
virus in DMEM and incubated at 37 1C for 2 days and then moved
to 34 1C for another 2 days.
Multi-step growth assays
Monolayer cultures of 2106 BSR cells or NA cells in 9-cm cell
culture dish were infected with virus at a multiplicity of infection
(MOI) of 0.01 ﬂuorescent focus units (FFU). Virus was adsorbed in
4 ml of growth medium for 1 h and then the cells were washed
thrice with PBS. Fresh growth medium was then added into the
cells and incubated at 37 1C. Samples of culture medium were
harvested at days 1, 2, 3, 4, and 5 post-inoculation. Virus titer was
determined in BSR cells by the dFA as previously described.
Interferon expression analysis using ELISA
BSR cells were infected with either the HEP-Flury, or rHEP-
CaIFNα1 virus at an MOI of 0.1, 0.5, or 1.0, respectively. After
incubation at 37 1C for 24 h, the culture supernatants were
harvested. Concentrations of CaIFNα1 in cell-free cell culture
supernatants were determined using an ELISA kit for canine
interferon alpha (Cloud-Clone, USA), according to the manufac-
turer's instructions.
CaIFNα1 treatment assay and immunoﬂuorescence microscopy
To conﬁrm the sensibility of mouse to canine interferon α1
(CaIFNα1), BSR cells, NA cells, and Balb/c-3T3 cells were seeded in
a glass bottom cell culture dish (NEST, China) and were incubated
with 500 U/ml CaIFNα1 (Pichia pastoris source, prepared by our
laboratory) at 37 1C for 1 h. Mock treatment was conducted by
inoculation with DMEM. After incubation step, the cells were ﬁxed
using Immunol Staining Fix Solution (Beyotime, China) for
10 min at room temperature and were permeabilized in 0.5%
TritonX-100 (Amresco, USA) in phosphate-buffered saline (PBS).
After incubation with pSTAT1(Y701)-PE (1:20 in PBS for 1 h
at 37 1C), nuclecular chromatin was stained by adding 40,6-diami-
dino-2-phenylindole (DAPI) (Beyotime, China).
Confocal laser scanning microscopy was performed with a Zeiss
LSM780 laser system using a Zeiss LSCM 7DUO microscope.
Excitation of Alexa Flour 488 nm, PE and DAPI occurred at
wavelengths of 575 nm, and 460 nm, respectively. To avoid cross
talk, the individual channels were scanned sequentially.
Apoptosis assay
To investigate the inﬂuence of canine interferon expressing by
rRABV on infected cells in vitro, detection of apoptosis by cyto-
metry analysis of annexin-V and propidium iodide (PI) staining
was conducted using Annexin V-FITC Apoptosis Detection Kit
(Keygentec, China). BSR cells and NA cells were infected with
either the HEP-Flury, or rHEP-CaIFNα1 at an MOI of 1.0, respec-
tively. After infected with virus for 24 h, both ﬂoating and
adherent cells were collected and processed as recommended by
the manufacturer. Flow cytometry was performed using a
Beckman FC 500 ﬂow cytometer (Beckman Coulter, USA).
Data were analyzed using FCS Express 4 ﬂow cytometry (De Novo
Software, USA).
Animal experiments
Chinese Kun Ming (KM) mice and BALB/c mice were used in
this research. For the pathogenicity study, BALB/c mice (6–7 weeks
of age) were infected intracranially with 105 FFU of either the HEP-
Flury, rHEP-CaIFNα1 or with medium alone (mock infection). Body
weight was monitored daily. Data were obtained from 5 mice in
each group for 30 days and presented as the mean value7stan-
dard error (SE). To investigate the immunogenicity of recombinant
RABV expressing CaIFNα1, groups of 10 KM mice (6–7 weeks of
age) were immunized via the intramuscular route with serial 10-
fold dilutions of HEP-Flury, or rHEP-CaIFNα1. At days 7, 14, and 21
after immunization, peripheral blood was obtained, and the serum
was used to determine virus neutralizing antibody (VNA) titers,
using an ELISA assay (Synbiotics, USA), according to the manufac-
turer's instructions. At day 23 after immunization, mice were
challenged intracranially with 50 LD50 CVS-24 and observed daily
for 2 weeks. The number of survivors was recorded and compared.
Data were analyzed using GraphPad Prism 5 (GraphPad software,
USA) with Gehan–Breslow–Wilcoxon Test or Log-rank (Mantel–
Cox) Test.
Quantitative real-time PCR
To evaluate interferon-induced gene expression at the inocula-
tion site, BALB/c mice (6–7 weeks of age) were inoculated via the
intramuscular route in the right hind leg with 105 FFU of one of the
recombinant viruses or with medium alone. After the mice were
humanely sacriﬁced, the right hind leg muscles of 4 mice from
each group were removed from infected mice at days 3 and 6 post-
infection and ﬂash frozen in liquid nitrogen before being stored at
80 1C. Total RNA was extracted using SV Total RNA Isolation
(Promega, USA) and used for ﬁrst strand cDNA synthesis (Roche,
GER) following the manufacturer's protocols. Each reaction was
carried out in triplicate using SsoAdvanced SYBR Green Supermix
(Bio-Rad, USA) according to the manufacturer's instructions.
The real-time SYBR Green PCR assay was carried out in a CFX384
Real-Time System (Bio-Rad, USA). The expression levels of target
genes, IIGP1, IRF3, PDCD4, STAT1, and mouse interferon alpha
(MusIFNα1), were normalized to those of the reference gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). In order
to analyze whether interferon-induced responses affected
viral growth in vivo, the RABV N mRNA and CaIFNα1 mRNA were
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quantitated relative to the GAPDH expression level. The primers
used to amplify target and reference genes are listed in Table 1.
Levels of interferon-induced gene expression in a test sample are
presented as the fold increase over those detected in sham-
infected controls.
Flow cytometry
To investigate effects of CaIFNα1 expression on the recruitment
of T cells in the peripheral blood and B cells in lymph nodes, ﬂow
cytometry was performed using a Beckman FC 500 ﬂow cytometer
(Beckman Coulter, USA). Brieﬂy, female BALB/c mice of 6–7 weeks
of age were inoculated intramuscularly with 105 FFU of one of the
recombinant RABVs or with medium alone. At days 3, 5, and
7 post-infection, the single-cell suspension of peripheral blood or
inguinal lymph nodes was harvested and stained with antibodies
to T cell- (FITC-CD3e, PerCP-CD4, and PE-CD8a) or B cell- (FITC-
CD19 and PE-CD40)markers (BD Biosciences Pharmingen, USA) for
15 min at room temperature (20–25 1C). A minimum of 100,000
events were counted. Data were analyzed using FCS Express 4 ﬂow
cytometry (De Novo Software, USA).
Statistical analysis
All experiments were repeated at least three times. Data were
analyzed using GraphPad Prism 5 (GraphPad software, USA), or
one-way ANOVA. Po0.05 was considered a signiﬁcant difference.
For all tests, the following notations are used to indicate signiﬁ-
cance between groups: npo0.05; nnpo0.01; nnnpo0.001.
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